| Esad Boskailo, MD | |
|
570 W Brown Rd, Mesa, AZ 85201-3227 | |
| (480) 344-2007 | |
| Not Available |
| Full Name | Esad Boskailo |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 39 Years |
| Location | 570 W Brown Rd, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245284660 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 30668 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Bridges Inc | 2062699721 | 73 |
| District Medical Group Inc | 7315086691 | 356 |
News Archive
ISPOR the professional society for health economics and outcomes research, examined the issue of patient access and biosimilars this afternoon at its ISPOR 2019 annual conference with the session, "Improving Patient Access to Life Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?"
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
Neuroscientists have failed to replicate the findings of an influential study linking genetics to cognition. Published in JNeurosci, the researchers highlight issues in the design, analysis, and interpretation of the original study.
Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.
Energy balance between energy intake and expenditure in our bodies is important for maintaining energy homeostasis to keep our bodies functioning properly. The appetite determines how much we eat, the energy intake, by communication between the brain and body.
› Verified 9 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
ISPOR the professional society for health economics and outcomes research, examined the issue of patient access and biosimilars this afternoon at its ISPOR 2019 annual conference with the session, "Improving Patient Access to Life Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?"
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
Neuroscientists have failed to replicate the findings of an influential study linking genetics to cognition. Published in JNeurosci, the researchers highlight issues in the design, analysis, and interpretation of the original study.
Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.
Energy balance between energy intake and expenditure in our bodies is important for maintaining energy homeostasis to keep our bodies functioning properly. The appetite determines how much we eat, the energy intake, by communication between the brain and body.
› Verified 9 days ago
| Entity Name | Community Bridges Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558095315 PECOS PAC ID: 2062699721 Enrollment ID: O20110606000388 |
News Archive
ISPOR the professional society for health economics and outcomes research, examined the issue of patient access and biosimilars this afternoon at its ISPOR 2019 annual conference with the session, "Improving Patient Access to Life Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?"
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
Neuroscientists have failed to replicate the findings of an influential study linking genetics to cognition. Published in JNeurosci, the researchers highlight issues in the design, analysis, and interpretation of the original study.
Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.
Energy balance between energy intake and expenditure in our bodies is important for maintaining energy homeostasis to keep our bodies functioning properly. The appetite determines how much we eat, the energy intake, by communication between the brain and body.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Esad Boskailo, MD 3255 E Elwood St, #110, Phoenix, AZ 85034-7256 Ph: (602) 470-5043 | Esad Boskailo, MD 570 W Brown Rd, Mesa, AZ 85201-3227 Ph: (480) 344-2007 |
News Archive
ISPOR the professional society for health economics and outcomes research, examined the issue of patient access and biosimilars this afternoon at its ISPOR 2019 annual conference with the session, "Improving Patient Access to Life Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?"
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
Neuroscientists have failed to replicate the findings of an influential study linking genetics to cognition. Published in JNeurosci, the researchers highlight issues in the design, analysis, and interpretation of the original study.
Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.
Energy balance between energy intake and expenditure in our bodies is important for maintaining energy homeostasis to keep our bodies functioning properly. The appetite determines how much we eat, the energy intake, by communication between the brain and body.
› Verified 9 days ago
Amol Rohit Patel, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2028 | |
Dr. Kate Gillpatrick, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 | |
Nancy L Vander Veer, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 602-344-2002 Fax: 480-649-0783 | |
Dr. Yaniv Simon, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2026 Fax: 480-344-0219 | |
Dr. Samuel Hutchinson, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4135 S Power Rd, Mesa, AZ 85212 Phone: 480-397-2830 | |
Payam M Sadr, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 Fax: 480-649-0783 | |
Troy Michael Fulton, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3707 E Southern Ave, Mesa, AZ 85206 Phone: 480-509-7738 |